Global Cardiovascular Diagnostics Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Cardiology diagnostics refer to tests performed to examine, check, and monitor the heart condition if an individual is suffering from cardiovascular diseases. There is an extensive range of diagnostic tests available such as ECG, invasive & non-invasive tests, cardiovascular autonomic reflex test, and other laboratory tests. A majority of the heart patients undergo a screening test, which is the first step in heart care. Diagnostic centers offer customized testing for each patient and ensure accurate diagnosis rapidly and cost-effectively. Cardiovascular diagnostics have created effective diagnostic solutions that support individuals in obtaining an accurate cardiac diagnosis, which help them to live longer and healthier. Most of the tests are performed to detect heart diseases well before an emergency event occurs. These tests are advanced, such as MRI, CT, ultrasound imaging, ECG, and offer point of care testing that provides effective results. These tests help to reduce the risk of mortality and offer strongly linked medical treatment in many emergency situations. Screening helps to determine the type of disease prior to the symptoms. The aim of screening tests is to provide the earliest and most desired treatment for the specific condition.
The cardiovascular diagnostics market is growing at a steady pace and is expected to grow at a rapid rate in the emerging countries. Factors, such as increasing lifestyle diseases, rise in smoking population, growing aging population, favorable reimbursements, and technological advancements in products, are driving the growth of the cardiovascular diagnostics market. However, the lack of awareness about diseases, stringent regulatory approval procedures, and risks associated with the procedure are hampering the market growth. The primary unmet need in the market is endoleaking, which increases the mortality rate.
The market is dominated by Abbott Laboratories, GE Healthcare, Philips Healthcare, Roche Diagnostics, and Bayer Healthcare, which have more than 85% of the share in the global cardiovascular diagnostics market.
Market Analysis: The global cardiovascular diagnostics market is estimated to witness a CAGR of 8.5% during the forecast period 2018–2024. The market is analyzed based on three segments, namely product type, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the cardiovascular diagnostics market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. The emerging markets have a high potential to grow owing to an increase in the number of patient population and focus toward healthcare infrastructure. The cardiovascular diagnostics market has the lowest penetration in the emerging markets, and most of the vendors are targeting to penetrate in countries such as India, China, Thailand, Vietnam, etc. However, the high cost of imaging modalities, expensive procedural costs, lack of skilled surgeons, lack of proper reimbursement policies, and lack of awareness about advanced diagnostic tools in the developing countries will have a significant impact on the overall market growth.
Product Analysis: The ECG segment is growing steadily and dominates the global cardiovascular diagnostics market with more than 37% of the total market share. Factors, such as increasing aging population, rise in the prevalence of CVDs, and growing adoption of POC testing devices are driving the market growth. The cardiac imaging segment is the most advanced and expected to overtake the ECG segment in coming years. The diagnosis and management of various cardiovascular diseases are increasingly growing with a large set of individuals depending on less-invasive imaging modalities such as CT angiography, cardiac magnetic resonance imaging (MRI), and cardiac radionuclide imaging such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). Advancements in medical imaging have increased the demand for image-guided diagnostics and surgical procedures, which have increased the usage of cardiac contrast media and radiopharmaceuticals.
Key Players: Abbott Laboratories, GE Healthcare, Philips Healthcare, Roche, Bayer Healthcare, and other predominate & niche players.
Competitive Analysis: The global cardiovascular diagnostics market is highly fragmented and has immense growth opportunities for vendors, especially in the developing regions. The market has the presence of many global, regional, and local players who are giving a stiff competition. The market is occupied by both global and local vendors who are competing to acquire the largest market share. Big players, such as Abbott Laboratories, GE Healthcare, Philips Healthcare, Roche, and Bayer Healthcare, are acquiring small players to increase their market share. The competitive environment in the market will intensify further with an increase in product/service extensions, product innovations, and M&As. They form strategic alliances for marketing or manufacturing of cardiovascular diagnostics devices.
Benefits: The report provides complete details about the usage and adoption rate of cardiovascular diagnostics for the treatment of various cardiac-related disorders. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Table of Contents
1 Industry Outlook 10
1.1 Industry Overview 10
1.2 Patient demographics 11
1.3 Healthcare Spending in the US 14
1.4 Definition: Cardiology Diagnostics 14
1.5 Why cardiovascular diagnostics? 14
1.6 Industry Trends 15
2 Report Outline 15
2.1 Report Scope 15
2.2 Report Summary 16
2.3 Research Methodology 17
2.4 Report Assumptions 17
3 Market Snapshot 18
3.1 Total Addressable Market (TAM) 18
3.2 Segmented Addressable Market (SAM) 20
3.3 Porter 5 (Five) Forces 22
4 Market Dynamics 23
4.1.1 Drivers 24
4.1.1.1 Increasing prevalence of cardiovascular diseases 24
4.1.1.2 Increasing geriatric population 25
4.1.1.3 Growing acceptance for minimally invasive endovascular surgeries 25
4.1.1.4 Increasing awareness towards point of care diagnostics in developing countries 25
4.1.1.1 Increase in healthcare spending 25
4.1.2 Restraints 26
4.1.2.1 High cost in installation and upgradation 26
4.1.2.2 Stringent regulations for approval 26
4.1.2.3 Intense competition among vendors 26
4.1.2.4 Lack of skilled healthcare professionals 27
4.1.2.5 Availability of alternative treatment procedure 27
4.1.3 Opportunities 27
4.1.3.1 Increase in demand for cardiac diagnostic imaging 27
4.1.3.2 Emergence of mHealth for improved outcome 27
4.1.3.3 Market expansion opportunities in emerging nations 28
4.1.3.4 Increasing number of insurance providers 28
4.1.4 DRO – Impact Analysis 29
4.1.5 Key Stakeholders 30
5 Product Types: Market Size & Analysis 31
5.1 Overview 31
5.2 ECG 34
5.2.1 Overview 34
5.3 Cardiac Imaging 35
5.3.1 Overview 35
5.4 Cardiac POC 36
5.4.1 Overview 36
5.5 Contrast Agents 38
5.5.1 Overview 38
6 End-user: Market Size and Analysis 40
6.1 Overview 40
6.2 Hospitals 41
6.3 Ambulatory Surgical Center 42
6.3.1 ASCs in the Americas 42
6.3.1.1 US 42
6.3.1.2 Canada 42
6.3.1.3 Mexico 43
6.3.2 ASCs in the EMEA Region 43
6.3.2.1 France 43
6.3.2.2 UK 43
6.3.2.3 Israel 43
6.3.2.4 Africa 43
6.3.3 ASCs in the APAC Region 43
6.3.3.1 Australia 43
6.3.3.2 India 43
6.3.3.3 China 43
6.4 Cardiac Centers 44
7 Regions: Market Size & Analysis 44
7.1 Overview 45
7.2 North America 46
7.2.1 Market Overview 46
7.3 Europe 47
7.3.1 Market Overview 47
7.4 APAC 49
7.4.1 Market Overview 49
7.4.2 Japan 50
7.4.3 China 50
7.4.4 India 50
7.5 Rest of the World 51
7.5.1 Market Overview 51
8 Competitive Landscape 54
8.1 Competitor Comparison Analysis 54
9 Vendor Profiles 56
9.1 Abbott Laboratories 56
9.1.1.1 Overview 56
9.1.2 Overview 56
9.1.3 Business Unit 59
9.1.4 Geographic Presence 60
9.1.5 Business Focus 61
9.1.6 SWOT Analysis 62
9.1.7 Business Strategy 62
9.2 F.Hoffmann-La Roche Ltd 63
9.2.1 Overview 63
9.2.2 Business Unit 66
9.2.3 Geographic Presence 67
9.2.4 Business Focus 68
9.2.5 SWOT Analysis 68
9.2.6 Business Strategy 69
9.3 GE Healthcare 70
9.3.1.1 Overview 70
9.3.1.2 Business unit 73
9.3.1.3 Business focus 74
9.3.1.4 SWOT analysis 74
9.4 Philips Healthcare 76
9.4.1.1 Overview 76
9.4.1.2 Business unit 80
9.4.1.3 Business focus 81
9.4.1.4 SWOT analysis 82
9.4.1.5 Business strategies 83
9.5 Siemens Healthineers Inc. (Siemens AG) 83
9.5.1 Overview 83
9.5.2 Business Units 86
9.5.3 Geographic Presence 88
9.5.4 Business Focus 88
9.5.5 SWOT Analysis 89
9.5.6 Business Strategy 89
10 Companies to watch for 90
10.1 Medtronic Plc 90
10.1.1 Key Highlights 90
10.1.2 Business Strategies 90
10.2 Hill-Rom Holdings, Inc 91
10.2.1 Overview 91
10.2.2 Key Highlights 92
10.2.3 Business Strategies 92
10.3 Qiagen N.V. 93
10.3.1 Overview 93
10.3.2 Key Highlights 93
10.3.3 Business Strategies 94
10.4 Boston Scientific Corp 97
10.4.1 Key Highlights 97
10.4.2 Business Strategies 97
10.4.3 Mortara Instruments 99
10.4.4 Key Highlights 99
10.4.5 Business Strategies 100
10.5 Instrumentation Laboratory (a Werfen company) 101
10.5.1 Overview 101
10.6 Becton Dickinson and Company 102
10.6.1 Overview 102
Annexure 104
Ø Acronyms 104
List of Tables
TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY 19
TABLE 2 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET BY TYPES, 2017–2024 ($MILLION) 33
TABLE 3 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET BY END-USERS 44
TABLE 4 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET REVENUE BY REGIONS FORECAST, 2017–2024 ($MILLION) 46
TABLE 5 DRO (NORTH AMERICA) 47
TABLE 6 DRO (EUROPE) 48
TABLE 7 DRO (APAC) 51
TABLE 8 DRO (REST OF THE WORLD) 53
TABLE 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS 56
TABLE 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 57
TABLE 11 F. HOFFMANN-LA ROCHE: OFFERINGS 63
TABLE 12 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 64
TABLE 13 GE HEALTHCARE: PRODUCT OFFERINGS 70
TABLE 14 GE HEALTHCARE: RECENT DEVELOPMENTS 70
TABLE 15 PHILIPS HEALTHCARE: PRODUCT OFFERINGS 76
TABLE 16 PHILIPS HEALTHCARE: RECENT DEVELOPMENTS 76
TABLE 17 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 83
TABLE 18 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 84
TABLE 19 MEDTRONIC PLC: SNAPSHOT 90
TABLE 20 MEDTRONIC PLC: RECENT DEVELOPMENTS 91
TABLE 21 HILL-ROM HOLDINGS, INC: SNAPSHOT 92
TABLE 22 HILL-ROM HOLDINGS, INC: RECENT DEVELOPMENTS 92
TABLE 23 QIAGEN N.V.: SNAPSHOT 94
TABLE 24 QIAGEN N.V.: RECENT DEVELOPMENTS 94
TABLE 25 BOSTON SCIENTIFIC CORP: SNAPSHOT 98
TABLE 26 BOSTON SCIENTIFIC CORP: RECENT DEVELOPMENTS 98
TABLE 27 MORTARA INSTRUMENTS: SNAPSHOT 100
TABLE 28 MORTARA INSTRUMENTS: RECENT DEVELOPMENTS 100
TABLE 29 INSTRUMENTATION LABORATORY: SNAPSHOT 101
TABLE 30 INSTRUMENTATION LABORATORY: RECENT DEVELOPMENTS 102
TABLE 31 BECTON DICKINSON AND COMPANY: SNAPSHOT 103
TABLE 32 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS 103
List of Charts
CHART 1 GLOBAL MEDICAL DEVICES MARKET SEGMENTATION 10
CHART 2 AGEING DEMOGRAPHIC GROWTH 12
CHART 3 US POPULATION DISTRIBUTION BY AGE (US, CENSUS BUREAU, CMS 2015) 13
CHART 4 US HEALTHCARE CONSUMPTION BY AGE (US, CENSUS BUREAU, CMS 2015) 13
CHART 5 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%) 14
CHART 7 RESEARCH METHODOLOGY 17
CHART 8 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION) 18
CHART 9 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET REVENUE, 2017-2024 ($MILLION) 20
CHART 10 PORTERS 5 FORCES ON CARDIOVASCULAR DIAGNOSTICS MARKET 22
CHART 11 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES 24
CHART 12 DRO - IMPACT ANALYSIS OF CARDIOVASCULAR DIAGNOSTICS MARKET 29
CHART 13 KEY STAKEHOLDERS 30
CHART 14 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET BY TYPE SEGMENTATION, 2017 (% SHARE) 31
CHART 15 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET BY TYPE SEGMENTATION, 2024 (% SHARE) 31
CHART 16 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET OVERVIEW BY PRODUCT TYPE 2017 32
CHART 17 GLOBAL ECG DEVICES MARKET BY REVENUE, 2017–2024 ($MILLION) 34
CHART 18 GLOBAL CARDIAC IMAGING MARKET BY REVENUE, 2017–2024 ($MILLION) 36
CHART 19 GLOBAL CARDIAC POC MARKET BY REVENUE, 2017–2024 ($MILLION) 37
CHART 20 GLOBAL CONTRAST AGENTS MARKET BY REVENUE, 2017–2024 ($MILLION) 39
CHART 21 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET SEGMENTATION BY PRODUCT TYPE, 2017-2024 ($MILLION) 39
CHART 22 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET SEGMENTATION BY PRODUCT TYPE, 2017-2024 (% SHARE) 39
CHART 23 GLOBAL CARDIOASCULAR DIAGNOSTIC MARKET BY END-USER SEGMENTATION, 2017 (% SHARE) 40
CHART 24 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017-2024 (%) 45
CHART 25 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET OVERVIEW BY REGIONS 2017 ($ MILLION) 45
CHART 26 CARDIOVASCULAR DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION) 47
CHART 27 CARDIOVASCULAR DIAGNOSTICS MARKET REVENUE IN THE EUROPE, 2017–2024 ($MILLION) 48
CHART 28 CARDIOVASCULAR DIAGNOSTICS MARKET REVENUE IN THE APAC, 2017–2024 ($MILLION) 50
CHART 29 CARDIOVASCULAR DIAGNOSTICS MARKET REVENUE IN THE REST OF THE WORLD, 2017–2024 ($MILLION) 52
CHART 30 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET SEGMENTATION BY GEOGRAPHY, 2017-2024 ($MILLION) 53
CHART 31 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET SEGMENTATION BY GEOGRAPHY, 2017-2024 (%) 54
CHART 32 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT 58
CHART 33 ABBOTT LABORATORIES.: BUSINESS UNITS 59
CHART 34 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE 60
CHART 35 ABBOTT LABORATORIES.: SWOT ANALYSIS 62
CHART 40 GE HEALTHCARE: OVERVIEW SNAPSHOT 71
CHART 41 GE HELATHCARE: BUSINES UNITS 73
CHART 42 GE HEALTHACRE: GEOGRAPHY 73
CHART 43 GE HEALTHCARE: SWOT ANALYSIS 74
CHART 44 PHILIPS HEALTHCARE: OVERVIEW SNAPSHOT 78
CHART 45 PHILIPS HELATHCARE: BUSINES UNITS 80
CHART 46 PHILIPS HEALTHACRE: FINANCES – GEOGRAPHY 80
CHART 47 PHILIPS HEALTHCARE: SWOT ANALYSIS 82
CHART 48 SIEMENS AG: OVERVIEW SNAPSHOT 86
CHART 49 SIEMENS AG: BUSINESS UNITS 86
CHART 50 SIEMENS AG: GEOGRAPHIC PRESENCE 88
CHART 51 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS 89
$2750
$3500
$4500
Add to Cart
Add to Cart
Add to Cart
Add to Cart